Tag: sacituzumab govitecan-hziy
Sacituzumab Govitecan Expected to Become Gilead’s Blockbuster Following Expanded Approval
In early February this year, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy®; Gilead Sciences) for the treatment of adult patients with...
Sacituzumab Govitecan Demonstrates Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2-...
Results from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating sacituzumab govitecan-hziy (Trodelvy®; Gilead Sciences) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients...
Withdrawal of FDA’s Accelerate Approved Therapeutic Agents may harm Patients
The United States Food and Drug Administration’s (FDA) program to accelerate approval of some promising therapeutic agents has recently come under fire due to...
